
Following the promising study on cannabinoids and COVID-19 published by Oregon State University, Gb Sciences, Inc. (OTCQB:GBLX), a plant-based biopharmaceutical research and development company, has advised that the truth behind how cannabinoids and terpenes work in therapeutic mixtures is more complicated than has been reported in the popular press.
Gb Sciences' study with Michigan State University (MSU) has yielded preclinical data demonstrating that specific compounds and ratios of those cannabis compounds are likely to be required for cannabinoids to be used to treat COVID-19 symptoms.